ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension

Roland E. Schmieder, Josep Redon, Guido Grassi, Sverre E. Kjeldsen, Giuseppe Mancia, Krzysztof Narkiewicz, Gianfranco Parati, Luis Ruilope, Philippe Van De Borne, Costas Tsioufis

Research output: Contribution to journalArticlepeer-review


Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.

Original languageEnglish
Pages (from-to)837-841
Number of pages5
JournalJournal of Hypertension
Issue number5
Publication statusPublished - May 2012


  • European Society of Hypertension
  • interventional therapy
  • resistant hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension'. Together they form a unique fingerprint.

Cite this